Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions in Saudi Arabia. SALT LAKE CITY, April 2, 2026/ PRNewswire/-- Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today...

#CODX Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Reports Full Year 2025 Financial Results Co-Diagnostics (NASDAQ: CODX) reported full year 2025 results and operational milestones on March 31, 2026. Revenue fell to $0.6M from $3.9M in 2024; operating expenses were $50.6M including an $18.9M intangible impairment. Net loss was $46.9M, or $35.25 per share; cash and securities totaled $11.9M.Operationally, Co-Dx closed equity offerings raising $10.8M, secured a CDSCO license in India, began instrument and TB test shipments to India, advanced CoSara and CoMira joint ventures, and expanded IP with new patents.

#CODX Co-Diagnostics Reports Full Year 2025 Financial Results

www.stocktitan.net/news/CODX/co-diagnostics...

WHO shifts TB guidance as Co-Diagnostics readies India studies India accounts for about 25% of global TB cases, and WHO's new guidance matches Co-Dx's near-point-of-care test design. Clinical studies are set to start soon.

#CODX Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization

www.stocktitan.net/news/CODX/co-diagnostics...

📢 Stocks Trending NOW: #SMCI #GE #PL #SPOT #FDX #DELL #CODX #AZTR #ARM #TSEM

Four new South Asian markets lift Co-Diagnostics' target to $13B Bangladesh, Pakistan, Nepal and Sri Lanka join CoSara’s territory, supporting rollout of PCR Pro and SARAGENE tests. Distributor session starts in Q2.

#CODX Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast Co-Diagnostics (Nasdaq: CODX) will release its Q4 and full year 2025 financial results on Tuesday, March 31, 2026 after market close. A conference call and webcast to discuss results will be held the same day at 4:30 p.m. ET.Management participants include Dwight Egan (CEO), Brian Brown (CFO) and Andrew Benson (Head of Investor Relations). The live webcast will be available at ir.co-dx.com and a replay will be posted on the company's website.

#CODX Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies Co-Diagnostics (Nasdaq: CODX) announced that the Japan Patent Office granted Japanese Patent No. 7797537 on March 12, 2026, titled "Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis."The patent, originally registered December 26, 2025, contains 34 claims covering the Co-Dx PCR Pro instrument, proprietary test cups, and core automated point-of-care PCR platform technologies, and follows a 2025 Australian patent. The company says this expands international IP protection while the platform remains subject to regulatory review and is not yet for sale.

#CODX Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies

www.stocktitan.net/news/CODX/co-diagnostics...

NEWS: ( OTC: #CODX ) Co-Diagnostics Inc. (NASDAQ: CODX) Rises Sharply in 1/14 Early Trading Session

Just In: ( NASDAQ: #CODX ) US Companies Moving the Markets, Evening edition <br>Tue, Jan 13, 2026 as of 4:00 pm ET

JUST IN: ( NASDAQ: #CODX ) Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

Lab conferences boost CoSara's India network for future TB PCR tests Co-Diagnostics JV CoSara joins 44th GAPM and 13th ACLAP meetings in India to showcase SARAGENE tests, add to 40+ distributors and prep MTB PCR studies.

#CODX Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics to Execute Reverse Stock Split to Regain Nasdaq Compliance Co-Diagnostics, Inc. announces a reverse stock split at a ratio of 1-for-30 shares to regain compliance with Nasdaq requirements, effective January 2, 2026.

Co-Diagnostics to Execute Reverse Stock Split to Regain Nasdaq Compliance #United_States #NASDAQ #Salt_Lake_City #Co-Diagnostics #CODX

Co-Diagnostics Announces Reverse Stock Split Co-Diagnostics (Nasdaq: CODX) filed a Certificate of Amendment to effect a 1-for-30 reverse stock split, effective at 12:01 a.m. ET on January 2, 2026. The company's common stock will continue trading on Nasdaq under the symbol CODX and will trade on a split-adjusted basis when markets open on January 2, 2026. The reverse split was approved by stockholders at a special meeting on December 5, 2025 within an authorized range of 1-for-2 to 1-for-30.The reverse split is intended to enable the company to regain compliance with Nasdaq's $1.00 minimum bid price requirement. At the effective time, every 30 issued and outstanding shares will combine into one share; par value per share remains unchanged. The action will adjust shares available under equity incentive plans, change option and warrant share counts and increase exercise prices, and result in a new CUSIP of 189763 204. Fractional shares will be rounded up to the next whole share.

#CODX Co-Diagnostics Announces Reverse Stock Split

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation Co-Diagnostics (Nasdaq: CODX) performed an in silico analysis of the Co-Primers used in its Logix Smart ABC test and reported high homology against 3,900 influenza sequences, finding comparable reactivity to influenza A H3N2 subclade K (J.2.4.1).The company noted the Logix Smart ABC test targets the MP gene while subclade K mutations occur in the HA region, and concluded no concern for reduced test sensitivity. The Logix Smart ABC test holds CE marking (November 2020) and is export-only. In November 2025 Co-Dx began clinical performance testing for a POC multiplex test intended to support a 510(k) submission to the FDA.

#CODX Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health Co-Diagnostics (Nasdaq: CODX) addressed tuberculosis testing adoption at The Union World Conference on Lung Health on Nov 20, 2025 in Copenhagen.The company highlighted its upcoming Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test Kit and a proprietary sample-preparation instrument for point-of-care testing on the Co-Dx PCR Pro platform. Co-Dx said it is planning clinical performance testing to begin soon and anticipates potential introduction to India and South Africa, noting a target of decentralized PCR access to nearly 30,000 primary health centers in India. Management also said it is exploring a possible strategic transaction, which may include a merger with a SPAC, for its Indian joint venture CoSara Diagnostics Pvt. Ltd. The Co-Dx PCR platform is under regulatory review and not available for sale.

#CODX Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Releases Financial Results for Third Quarter of 2025, Celebrating Strategic Ventures Co-Diagnostics, Inc. announces its third quarter financial results for 2025, emphasizing strategic partnerships, an AI unit launch, and focused product development.

Co-Diagnostics Releases Financial Results for Third Quarter of 2025, Celebrating Strategic Ventures #USA #Salt_Lake_City #Co-Diagnostics #CODX #Co-Dx

#CODX Co-Diagnostics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd Co-Diagnostics (NASDAQ: CODX) announced on November 5, 2025 that it has engaged Maxim Group as exclusive financial advisor to explore strategic alternatives for its Indian joint venture, CoSara Diagnostics Pvt. Ltd.Options being pursued include a merger with a SPAC or similar U.S.-listed entity on a national securities exchange. CoSara, established in 2017, is a joint venture between Co-Diagnostics and Synbiotics, part of Asence and Ambalal Sarabhai Enterprises (Bombay Stock Exchange-listed). CoSara intends to manufacture and sell molecular diagnostics products with an initial focus on India and certain international markets.

#CODX Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform Co-Diagnostics (Nasdaq: CODX) announced the formation of a new artificial intelligence business unit, led by Chief Technology &amp; AI Officer Christopher Thurston, to consolidate the company’s AI initiatives into the Co-Dx Primer Ai platform.The company said the unit aims to accelerate development of proprietary AI-powered PCR diagnostics, support Co-Primers design and workflow orchestration, enable automated test interpretation, and integrate analytics via a HIPAA-compliant Co-Dx cloud. The release notes the Co-Dx PCR platform remains subject to FDA and other regulatory review and is not available for sale.

#CODX Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

www.stocktitan.net/news/CODX/co-diagnostics...

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #INVZ 1552.6x
2. #CODX 951.0x
3. #CMBM 700.2x
4. #SW 185.4x
5. #HLF 50.9x

#OptionFlow #OptionsTrading #Trading

Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast Co-Diagnostics (NASDAQ: CODX) will release its third quarter 2025 financial results on Thursday, November 13, 2025 after the market close.The company will host a conference call and webcast the same day at 4:30 p.m. ET with Dwight Egan (CEO), Brian Brown (CFO), and Andrew Benson (Head of Investor Relations). The live webcast is available at ir.co-dx.com on the Events &amp; Webcasts page, and the conference call numbers are 1-888-880-3330 (toll free) and 1-646-357-8766 (toll). A recorded replay will be posted on the company's website for those unable to attend live.

#CODX Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics Closes $7 Million Stock Offering to Boost Operations and Growth Co-Diagnostics, Inc. recently closed a $7 million stock offering to support its growth and operational activities, enhancing its molecular diagnostics capabilities.

Co-Diagnostics Closes $7 Million Stock Offering to Boost Operations and Growth #United_States #Salt_Lake_City #Molecular_Diagnostics #Co-Diagnostics #CODX

Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules SALT LAKE CITY, Oct. 28, 2025/ PRNewswire/-- Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a securities purchase agreement with several institutional investors for the purchase and sale of 12,727,272 shares of common stock at an...

#CODX Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/CODX/co-diagnostics...

📢 Stocks Trending NOW: #PYPL #SOFI #UNH #UPS #GPUS #QCOM #RCL #GLW #CODX #CCJ

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CODX 90% OTM
2. #KYTX 59% OTM
3. #BIDU 55% OTM
4. #ASST 51% OTM
5. #RGTI 50% OTM

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ASST 27.0x
2. #HUN 19.3x
3. #QCOM 16.5x
4. #VFC 9.0x
5. #CODX 5.3x

#OptionFlow #OptionsTrading #Trading

Breaking News: ( NASDAQ: #CODX ) Co-Diagnostics, Inc. (Nasdaq: CODX) Leads Nasdaq Top Gainers on new Saudi-based CoMira Diagnostics joint venture

Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing Co-Diagnostics (Nasdaq: CODX) announced development of a proprietary sample preparation instrument for its point-of-care Co-Dx PCR MTB test, designed for low-cost, user-friendly sample processing in resource-limited settings. The device supports sputum and a novel tongue swab method, uses single-button operation with no measuring tools, and includes a built-in safety feature to inactivate live organisms. Clinical evaluations in India for the MTB test are expected to begin before year-end 2025. Manufacturing is anticipated with Systronics under India’s "Make in India" initiative.

#CODX Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing

www.stocktitan.net/news/CODX/co-diagnostics...

Co-Diagnostics, Inc. Set to Engage with Investors at 2025 Maxim Growth Summit Co-Diagnostics, Inc. plans to participate in the 2025 Maxim Growth Summit, featuring industry leaders and discussions on diverse topics including biotechnology and AI.

Co-Diagnostics, Inc. Set to Engage with Investors at 2025 Maxim Growth Summit #United_States #New_York #NASDAQ #Co-Diagnostics #CODX